US 11,904,126 B2
Cryo formulation-based microneedle device for transdermal delivery of bioactive therapeutic agents and performing vaccination using a cryo-microneedle patch
Chenjie Xu, Kowloon (HK); and Hao Chang, Kowloon (HK)
Assigned to City University of Hong Kong, Kowloon (HK)
Filed by City University of Hong Kong, Kowloon (HK)
Filed on Jul. 27, 2021, as Appl. No. 17/443,513.
Claims priority of provisional application 63/071,491, filed on Aug. 28, 2020.
Prior Publication US 2023/0033564 A1, Feb. 2, 2023
Prior Publication US 2023/0285730 A9, Sep. 14, 2023
Int. Cl. A61M 37/00 (2006.01)
CPC A61M 37/0015 (2013.01) [A61M 2037/0023 (2013.01); A61M 2037/0053 (2013.01); A61M 2037/0061 (2013.01); A61M 2202/0007 (2013.01); A61M 2202/03 (2013.01); A61M 2202/07 (2013.01); A61M 2202/30 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A cryo formulation-based microneedle device for transdermal delivery of bioactive therapeutic agents, comprising:
one or more microneedle patches each including an array of miniaturized needles, each miniaturized needle defining a base end and a tip; and
a substrate to which the base end of the array of miniaturized needles is attached or integrated thereto;
wherein the microneedle patches are in a cryo status;
wherein each of the one or more microneedle patches are adapted to be applied on a skin surface, in which the miniaturized needles penetrate into skin;
wherein the miniaturized needles are further arranged to melt so as to release one or more bioactive therapeutic agents into the skin to achieve a targeted therapeutic effect;
wherein each of the one or more microneedle patches consists of a matrix solution and one or more bioactive therapeutic agents; and
wherein the one or more bioactive therapeutic agents includes at least one of a spike glycoprotein, a nucleocapsid protein, mRNA for encoding a spike glycoprotein, mRNA for encoding a nucleocapsid protein, and a combination thereof.